Back to top

Analyst Blog

In an attempt to further strengthen its Life Sciences business, Pall Corporation (PLL - Analyst Report), on Feb 20, completed the acquisition of ATMI LifeSciences business. The deal, valued at $185 million, was announced to have closed in fiscal third quarter. The decision to acquire ATMI was announced on Dec 23, 2013. This acquisition is estimated to be immediately accretive to Pall’s revenues, while being slightly dilutive to its earnings in fiscal 2014.  

The purchase is a strategic move as it complements Pall’s existing Life Sciences segment business. It supports Pall’s current offering and broadens its already extensive portfolio of advanced solutions for biopharmaceutical customers.

ATMI, Inc. is a global provider of specialty semiconductor materials, safe, high-purity materials handling and delivery solutions. ATMI LifeSciences is a technology leader in the area of single-use bioprocess systems and consumables for the pharmaceutical and biopharmaceutical industries. It has an innovative, market-leading portfolio of custom-engineered, flexible packaging solutions, single-use storage systems, mixers and bioreactors. These businesses are driving bioprocess efficiency and delivering value for biopharmaceutical companies across the world.

Pall Corp’s Life Sciences segment is one of the primary contributors to its top-line improvement with a 7% year-over-year revenue growth in the last reported quarter.  This increase was driven by a 5% rise in the Biopharmaceuticals segment, which in turn was aided by new products; 6% growth in the Food & Beverage division driven by strong performance across regions; and a 17% improvement in the Medical segment, on the back of strong sales to OEMs.

Pall Corp. carries a Zacks Rank #3 (Hold). Investors interested in the pollution control industry may consider stocks like Sharps Compliance Corp. (SMED - Snapshot Report) with a Zacks Rank #1 (Strong Buy) and Tetra Tech Inc. (TTEK - Analyst Report) and Pure Cycle Corp. (PCYO - Snapshot Report), carrying a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.